Tyra Biosciences (TYRA) Research & Development (2020 - 2026)
Tyra Biosciences' (TYRA) quarterly Research & Development came in at $33.5 million in Q1 2026, up 34.07% YoY from $25.0 million in Q1 2025, and up 18.75% on a QoQ basis from $28.2 million in Q4 2025.
Tyra Biosciences (TYRA) Research & Development (2020 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 7 years of Research & Development data on file, last reported at $33.5 million in Q1 2026.
- Quarterly Research & Development rose 34.07% year-over-year to $33.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $111.4 million (up 26.86% YoY) and the FY2025 annual result came in at $102.9 million, up 28.54% from the prior year.
- Research & Development climbed to $33.5 million in Q1 2026, from $28.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $33.5 million in Q1 2026 to a low of $9.6 million in Q1 2022.
- A 5-year average of $18.9 million and a median of $19.3 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 174.98% — and 2023, when it climbed 0.95%.
- Tracing TYRA's Research & Development over 5 years: stood at $10.4 million in 2022, then soared by 98.82% to $20.7 million in 2023, then rose by 7.27% to $22.2 million in 2024, then increased by 27.08% to $28.2 million in 2025, then gained by 18.75% to $33.5 million in 2026.
- The last three Research & Development figures came in at $33.5 million (Q1 2026), $28.2 million (Q4 2025), and $25.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Tyra Biosciences | 1.51 Bn | 1.51 Bn | - | 39.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.20 Mn |
| Mar 31, 2026 | 33.47 Mn |
| Dec 31, 2025 | 28.19 Mn |
| Sep 30, 2025 | 25.47 Mn |
| Jun 30, 2025 | 24.31 Mn |
| Mar 31, 2025 | 24.96 Mn |
| Dec 31, 2024 | 22.18 Mn |
| Sep 30, 2024 | 22.70 Mn |
| Jun 30, 2024 | 18.00 Mn |
| Mar 31, 2024 | 17.20 Mn |
| Dec 31, 2023 | 20.68 Mn |
| Sep 30, 2023 | 19.27 Mn |
| Jun 30, 2023 | 12.16 Mn |
| Mar 31, 2023 | 10.41 Mn |
| Dec 31, 2022 | 10.40 Mn |
| Sep 30, 2022 | 10.92 Mn |
| Jun 30, 2022 | 12.05 Mn |
| Mar 31, 2022 | 9.65 Mn |
| Dec 31, 2021 | 7.25 Mn |
| Sep 30, 2021 | 5.48 Mn |